Jauhiainen K, Kangas L, Nieminen A L, Käpylä H, Alfthan O
Urol Res. 1983;11(2):59-62. doi: 10.1007/BF00256948.
Walker 256 carcinosarcoma was shown to be sensitive to mitomycin C in vitro. In order to make practical recommendations for the clinical intravesical use of mitomycin C, this cell line was used to evaluate the activity of mitomycin C under different conditions. Mitomycin C loses its antitumour activity rapidly at pH's below 6. At higher pH's (up to 10) mitomycin C is stable and suitable for intravesical application. To secure a sufficiently high pH in the bladder during intravesical treatment, phosphate buffer 0.05 M with a pH of 7.4 is recommended. Constituents of urine very little decrease the activity of buffered mitomycin C during a 2 h application. Prednisolone, which has been suggested to prevent the harmful chemical cystitis, has no inhibitory effect on the activity of mitomycin C.
沃克256癌肉瘤在体外显示对丝裂霉素C敏感。为了对丝裂霉素C临床膀胱内使用提出切实可行的建议，使用该细胞系评估不同条件下丝裂霉素C的活性。丝裂霉素C在pH值低于6时会迅速失去其抗肿瘤活性。在较高pH值（高达10）时，丝裂霉素C是稳定的，适合膀胱内应用。为了在膀胱内治疗期间确保膀胱内有足够高的pH值，建议使用pH值为7.4的0.05M磷酸盐缓冲液。在2小时的应用过程中，尿液成分对缓冲后的丝裂霉素C活性几乎没有降低作用。已被建议用于预防有害化学性膀胱炎的泼尼松龙对丝裂霉素C的活性没有抑制作用。
